Phase 1/2a trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors

CONCLUSIONS: BMS-986148 {plus minus} nivolumab demonstrated a clinically manageable safety profile and preliminary evidence of clinical activity, supporting additional studies combining directed cytotoxic therapies with checkpoint inhibitors as potential multimodal therapeutic strategies in patients with advanced solid tumors.PMID:34615718 | DOI:10.1158/1078-0432.CCR-21-1181

Source: Clinical Cancer Research - October 7, 2021 Category: Cancer & Oncology Authors: Sylvie Rottey Jeffrey Clarke Kyaw Aung Jean-Pascal Machiels Ben Markman Kimberley M Heinhuis Michael Millward Martijn Lolkema Sandip Pravin Patel Paul de Souza Matteo Duca Giuseppe Curigliano Armando Santoro Takafumi Koyama Michelle Brown Heather Vezina C Source Type: research